The missing piece of the puzzle
Supplementing disease modelling with microbiome data is set to enable the life sciences industry to understand more about how drugs interact with different people, and devise more targeted treatments. Anthony Finbow explains how the science of microbiomes will increasingly contribute to pharma research outcomes
Read More
